MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$22,999K
Proceeds from issuance of
warrants in connection...
$15,520K
Proceeds from issuance of
common stock and...
$5,980K
Proceeds from issuance of
common stock
$5,805K
Proceeds from funding
agreement, related party
$1,000K
Exercise of warrants
$820K
Exercise of stock options
$352K
Net cash provided by
financing activities
$50,023K
Canceled cashflow
$2,453K
Net increase
(decrease) in cash and cash...
$14,770K
Canceled cashflow
$35,253K
Issuance costs
attributed to equity...
$2,301K
Share repurchases for
the payment of...
$152K
Fair value change in
warrant and other...
-$11,515K
Stock-based compensation
$3,399K
Accounts receivable
-$1,568K
Warrant financing costs
$1,337K
Contract assets and
unbilled receivables
-$1,039K
Non-cash interest
$129K
Non-cash share issuances
$57K
Depreciation
$53K
Accounts payable
$7K
Unrealized loss from
short-term investments
-$2K
Net cash used in
operating activities
-$35,253K
Canceled cashflow
$19,106K
Net loss
-$49,591K
Accrued expenses and
other liabilities
-$3,495K
Prepaid expenses and
other assets
$1,273K
Back
Back
Cash Flow
source: myfinsight.com
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)